Literature DB >> 29729169

Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome.

Liliya S Babinets1, Nataliia A Melnyk1, Nataliia O Shevchenko1, Galina M Sasyk1, Olexandr S Zemlyak1, Olexandra Ye Kopach1, Olga Ye Fedoriv1.   

Abstract

OBJECTIVE: Inroduction: The most common reasons of chronic pancreatitis are alcohol abuse, biliary tract and liver diseases, stomach and duodenum, hyperlipidemia, which is often associated with metabolic syndrome. The aim: to study the effectiveness of using medicine omega-3 polyunsaturated fatty acids in standard therapy to the correction of lipids and prooxidant-antioxidant disorders in patients with chronic pancreatitis and metabolic syndrome. PATIENTS AND METHODS: Materials and methods: The study included 90 patients with chronic pancreatitis with metabolic syndrome. They were divided into two groups: I group (45 patients) received standard treatment; II group (45 patients) along with baseline therapy received medication omega-3 polyunsaturated fatty acids (Omacor) for 2 capsules (1680 mg) for one month.
RESULTS:
Results: After treatment the lipid blood spectrum and prooxidant-antioxidant status have improved.
CONCLUSION: Conclusions: Adding to the complex therapy of patients with chronic pancreatitis and the metabolic syndrome of the medicine omega-3 polyunsaturated fatty acids helps to improve the lipid and prooxidation-antioxidant status more significantly compared with standard baseline therapy.

Entities:  

Keywords:  chronic pancreatitis ; metabolic syndrome ; omega-3 polyunsaturated fatty acids ; treatment

Mesh:

Substances:

Year:  2018        PMID: 29729169

Source DB:  PubMed          Journal:  Wiad Lek        ISSN: 0043-5147


  1 in total

1.  Changes of pro- and antioxidant indicators in experimental animals under acute small bowel obstructions.

Authors:  Svitlana Romanivna Pidruchna; Volodymyr Volodymyrovych Benedyct; Volodymyr Ivanovych Piatnochka; Nataliia Anatoliiivna Melnyk; Uliana Mykhailivna Zakharchuk
Journal:  J Med Life       Date:  2021 Jan-Mar
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.